IgAN/FSGS Monitoring Program | Q2 2026
This educational material is in development by independent expert faculty. Support for this activity is being sought through unrestricted educational grants. If supported, supporters will have no role in faculty selection, content development, conclusions, or dissemination.
Status: In development; support not yet awarded.
Practical frameworks for monitoring cadence tradeoffs (frequency, patient burden, cost, actionable yield) and evaluation decision points in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).
Covers: what monitoring changes should trigger additional testing, closer follow-up, or escalation of evaluation, and what patterns typically do not warrant escalation. This material does not provide treatment recommendations.
Content forthcoming
Expected ~30 days post-session